Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate — MTX  

External Causes of Morbidity and Mortality Clinical Trial

Official title: Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate Enroled in the Ratingener Rheuma-Kohorte

Status Completed

Clinical Trial Summary

Longterm followup of patients with rheumatoid arthritis 30 years after starting a baseline treatment with Methotrexate.

Clinical Trial Description

Objective. 30-year follow-up of rheumatoid arthritis (RA) patients treated with methotrexate (MTX) in the 1980s to analyze the association of the degree of response to MTX with long-term mortality.

Methods. In this observational cohort study, 271 RA patients who had started treatment with MTX between 1980 and 1987 were included (mean age 58 years, mean disease duration 8.5 years). One year after baseline, the treatment response to MTX was evaluated. Responders were defined as patients with at least 20% improvement. Thereafter, assessments were performed at 10 and 18 years after baseline. This re-evaluation was done to provide the data after 30 years of follow-up. Standardized mortality ratios (SMR) are calculated, Cox regression and logistic regression are performed. ;

Related Conditions & MeSH terms

• Arthritis, Rheumatoid
• External Causes of Morbidity and Mortality

• NCT number: NCT02641977
• Study type: Observational
• Source: Ruhr University of Bochum
• Status: Completed
• Start date: August 2015
• Completion date: August 2016